Spruce Biosciences, Inc. (SPRB) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Bionano Genomics, Inc.

Cue Biopharma, Inc.

CARA Therapeutics, Inc.

Immunome, Inc.

NGM Biopharmaceuticals, Inc.

Armata Pharmaceuticals, Inc.

Kodiak Sciences, Inc.

Cyteir Therapeutics, Inc.

Anixa Biosciences, Inc.

Spruce Biosciences, Inc.

IO Biotech, Inc.

Why is Spruce Biosciences, Inc. ?

Unrated Stock - No Analysis Available

Real-Time Research Report

Verdict Report

No Data Found

Is Spruce Biosciences, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Spruce Biosciences, Inc.

133.04%

1.00

8463.13%

S&P 500

16.12%

0.84

19.28%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

11.20%

EBIT Growth (5y)

-153.38%

EBIT to Interest (avg)

-47.00

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.56

Sales to Capital Employed (avg)

0.12

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

89.59%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

15.53

EV to EBIT

-1.49

EV to EBITDA

-1.49

EV to Capital Employed

-16.64

EV to Sales

73.81

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-895.62%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

4What is working for the Company

NET PROFIT(HY)

Higher at USD -10.64 MM

DEBT-EQUITY RATIO (HY)

Lowest at -173.06 %

-7What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at USD -47.56 MM

ROCE(HY)

Lowest at -167.93%

RAW MATERIAL COST(Y)

Grown by 101.03% (YoY

CASH AND EQV(HY)

Lowest at USD 27.06 MM

Here's what is working for Spruce Biosciences, Inc.

Net Profit

Higher at USD -10.64 MM

than preceding 12 month period ended Sep 2025

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Debt-Equity Ratio

Lowest at -173.06 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Here's what is not working for Spruce Biosciences, Inc.

Operating Cash Flow

Lowest at USD -47.56 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Cash and Eqv

Lowest at USD 27.06 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Raw Material Cost

Grown by 101.03% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales